Arch Oncology Is A Clinical Stage Immuno Oncology Company Based In Brisbanecaliforniawith A Research Laboratory In Stlouismissourithe Company Specializes In Developing Antibody Therapies Targeting Cancerparticularly Through Next Generation Anti Cd47 Biologicsarch Oncology Is Dedicated To Discoveringbest In Classtherapies For Solid Tumors And Hematologic Malignancies The Company S Lead Candidateao 176Is An Anti Cd47 Igg2 Antibody Designed To Enhance Safety And Efficacy Compared To Earlier Therapiesao 176 Works By Blocking Thedonae T Eat Mesignal On Tumor Cellspromoting Direct Tumor Cell Killing And Triggering Immunogenic Cell Deathit Is Currently Undergoing Phase 1 2 Clinical Trials For Various Cancersincluding Ovarian And Colorectal Cancersas Well As Multiple Myelomaarch Oncology Has Received U Sfda Orphan Drug Designation For Ao 176 In Multiple Myelomahighlighting Its Potential In The Oncology Fieldthe Company Is Also Developing Additional Anti Cd47 Antibody Programs To Further Improve Treatment Options
